Regarding the news that Novo Nordisk will limit the sales of the 'weight loss miracle drug' Wegovy (Chinese trade name: Nuoyaying) in China, Novo Nordisk responded to reporters that Nuoyaying has been launched in more than 10 countries globally. In order to meet the needs of patients, the company is working hard to increase the supply of GLP-1 drugs. The company will distribute existing product supplies in a responsible manner in the global market, following consistent standards, focusing on ensuring the continuity of patient medication and the accessibility of innovative drugs. On June 27th, it was reported in the media that Maziar Mike Doustdar, head of Novo Nordisk's international business, said that the company will limit the sales of its heavyweight weight loss drug Wegovy in China to avoid the influx of Chinese patients causing a shortage of drug supply in other parts of the world.